Treating hypertension in women of child-bearing age and during pregnancy

Drug Safety

Volumn 24, Issue 6, 2001, Pages 457-474

  Magee, Laura A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; LABETALOL; LOSARTAN; METHYLDOPA; NIFEDIPINE; NITROPRUSSIDE SODIUM; ORAL CONTRACEPTIVE AGENT; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; TRIAMTERENE; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BIRTH DEFECT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; LIFESTYLE; MATERNAL HYPERTENSION; MATERNAL MORTALITY; ORAL CONTRACEPTION; PERINATAL MORTALITY; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TERATOGENICITY; TREATMENT INDICATION;

EID: 0034999566     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124060-00004     Document Type: Review

References (134)

1. Joint National Committee on detection, evaluation, and treatment of high blood pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Int Med 1997; 157: 2413-46
2. Feldman RD, Campbell N, Larochelle P, et al. Task Force for the development of the 1999 Canadian recommendations for the treatment of hypertension. CMAJ 1999; 161 (12 Suppl.): S1-S22
3. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630-5
4. Joffres MR, Hamet P, Rabkin SW, et al. Prevalence, control and awareness of high blood pressure among Canadian adults. CMAJ 1992; 146 Suppl.: 28-36
5. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
6. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement f-or health professionals. Circulation 1991; 83: 356-62
7. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993; 307, 107-10
8. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4: 265-71
9. Who Expert Committee. Hypertension control. Geneva: World Health Organization, 1996, Report no.: 862
10. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739-45
11. Skrabanek P. Smoking and statistical overkill. Lancet 1992; 340: 1208-9
12. Magee LA, de Swiet M. Medical diseases in early pregnancy. In: Jauniaux E, Barnea ER, Edwards R, editors. Embryonic medicine and therapy. Oxford: Oxford University Press, 1997: 390-439
13. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
14. Poppas A, Shroff SG, Korcarz CE, et al. Serial assessment of the cardiovascular system in normal pregnancy: role of arterial compliance and pulsatile arterial load. Circulation 1997; 95: 2407-15
15. August P, Lenz T, Ales KL, et al. Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: deviations related to development of super-imposed preeclampsia. Am J Obstet Gynecol 1990; 163: 1612-21
16. Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol 1986; 67: 517-22
17. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Consensus statement from the Australasian Society for the Study of Hypertension in Pregnancy. Aust N Z J Obstet Gynaecol 2000; 40: 133-8
18. Helewa M, Burrows RF, Smith J, et al. Report of the Canadian Hypertension Society consensus conference: 1. Definitions, evaluation and classification of hypertension disorders in pregnancy. CMAJ 1997; 157: 715-25
19. Shennan A, Bupta M, Halligan A, et al. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996; 347: 139-42
20. Peek M, Shennan A, Halligan A, et al. Hypertension in pregnancy: which method of blood pressure measurement is most predictive of outcome? Obstet Gynecol 1996; 88: 1030-3
21. Penny JA, Halligan AWF, Shennan AH, et al. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Obstet Gynecol 1998; 178: 521-6
22. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Clin Exp Hypertens Pregnancy 1986; B5: 97-133
23. Khong TY, De Wolf F, Robertson WB, et al. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-59
24. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341: 1447-51
25. Friedman SA, Lindheimer MD. Prediction and differential diagnosis. In: Lindheimer MD, Roberts JM, Cunningham FG, editors. Chesley's hypertensive disorders in pregnancy. 2nd ed. Stamford (CT): Appleton & Lange, 1999: 201-27
26. Saftlas AF, Olson DR, Franks AL, et al. Epidemiology of pre-eclampsia and eclampsia in the United States. 1979-1986. Am J Obstet Gynecol 1990; 163: 460-5
27. National High Blood Pressure Education Program Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol 1990; 163: 1689-712
28. Lindberg BS. Epidemiology of hypertension during pregnancy. Int J Technol Assess Health Care 1992; 8 (Suppl.): 57-62
29. Page EW, Christianson R. Influence of blood pressure changes with and without proteinuria upon outcome of pregnancy. Am J Obstet Gynecol 1976; 126: 821-33
30. Wittmann BK, Murphy KJ, King JF, et al. Maternal mortality in British Columbia in 1971-86. CMAJ 1988; 139: 39-40
31. Department of Health. Why mothers die. Report on confidential enquiries into maternal deaths in the United Kingdom 1994-1996. London: HMSO, 1998
32. Department of Health. Report on confidential enquiries into maternal deaths in England and Wales 1982-84. London: HMSO, 1989
33. Magee LA, Ornstein MP. von Dadelszen P, Clinical review: management of mild to moderate pregnancy hypertension. BMJ 1999; 318: 1332-8
34. Burrows RF, Burrows EA. The need for seizure prophylaxis in preeclampsia is still unresolved. Am J Obstet Gynecol 1996; 174: 800-1
35. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341: 1447-51
36. Douglas KA, Redman CWG. Eclampsia in the United Kingdom. BMJ 1994; 309: 1396-400
37. Misra DP. The effect of the pregnancy-induced hypertension on fetal growth: a review of the literature. Paediatr Perinatol Epidemiol 1996; 10: 244-63
38. Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000; 96: 849-60
39. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994; 171: 410-6
40. Ferrazzani S, Caruso A, De Carolis S, et al. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol 1990; 162: 366-71
41. Mabie WC, Pernoll ML, Biswas MK. Chronic hypertension in pregnancy. Obstet Gynecol 1986; 67: 197-205
42. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients with mild chronic hypertension. Obstet Gynecol 1983; 61: 571-6
43. Sibai BM, Lindheimer M, Hauth J, et al., National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. N Engl J Med 1998; 339: 667-71
44. Hauth JC, Ewell MG, Levine RJ, et al., Calcium for Preeclampsia Prevention Study Group. Pregnancy outcomes in healthy nulliparas who developed hypertension. Obstet Gynecol 2000; 95: 24-8
45. Saudan P, Brown MA, Buddle ML, et al. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 1998; 105: 1177-84
46. Barton JR, O'Brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term: progression and outcome [abstract]. Am J Obstet Gynecol 1999; 180: S48
47. Horsager R, Adams M, Richey S, et al. Outpatient management of mild pregnancy induced hypertension. 15th Annual Meeting of the Society of Perinatal Obstetricians; 1995; Atlanta
48. Eskenazi B, Fenster L, Sidney S, et al. Fetal growth retardation in infants of multiparous and nulliparous women with pre-eclampsia. Am J Obstet Gynecol 1993; 169: 1112-8
49. Friedman EA, Neff RK. Pregnancy outcome as related to hypertension, edema, and proteinuria. In: Lindheimer MD, Katz AL, Zuspan FP, editors. Hypertension in pregnancy. New York (NY): John Wiley & Sons, 1976: 13-22
50. van Pampus MG, Wolf H, Westenberg SM, et al. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1998; 76: 31-6
51. Sibai BM, Barton JR, Akl S, et al. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992; 167: 879-84
52. Naeye RL, Friedman EA. Causes of perinatal death associated with gestational hypertension and proteinuria. Am J Obstet Gynecol 1979; 133: 8-10
53. Sibai BM, Spinnato JA, Watson DL, et al. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol 1984; 64: 319-25
54. Visser W, Wallenburg HCS. Maternal and perinatal outcome of temporizing management in 154 consecutive patients with severe pre-eclampsia remote from term. Eur J Obstet Gynecol Reprod Biol 1995; 63: 147-54
55. Pietrantoni M, O'Brien WF. The current impact of the hypertensive disorders of pregnancy. Clin Exp Hypertens 1994; 16: 479-92
56. Eskenazi B, Fenster L, Sidney S, et al. Fetal growth retardation in infants of multiparous and nulliparous women with pre-eclampsia. Am J Obstet Gynecol 1993; 169: 1112-8
57. Sibai BM, Barton JR, Akl S, et al. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992; 167: 879-84
58. Sibai BM, Gonzalez AR, Mabie WC, et al. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987; 70: 323-7
59. Moore MP, Redman CWG. Case-control study of severe pre-eclampsia of early onset. BMJ 1983; 287: 580-3
60. Long PA, Abell DA, Beischer NA. Fetal growth retardation and pre-eclampsia. Br J Obstet Gynaecol 1980; 87: 13-8
61. Gilstrap LC, Cunningham FG, Whalley PJ. Management of pregnancy induced hypertension in the nulliparous patient remote from term. Semin Perinatol 1978; 2: 73-81
62. Lapillonne A, Peretti N, Ho PS, et al. Aetiology, morphology and body composition of infants born small for gestational age. Acta Paediatr 1997; 423 Suppl.: 173-6
63. Bernstein IM, Horbar JD, Badger GJ, et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. Am J Obstet Gynecol 2000; 182: 198-206
64. McIntire DD, Bloom SL, Casey BM, et al. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999; 340: 1234-8
65. Tyson JE, Kennedy K, Broyles S, et al. The small for gestational age infant: accelerated or delayed pulmonary maturation? Increased or decreased survival. Pediatrics 1995; 95: 534-8
66. Badawi N, Kurinezuk JJ, Keogh JM, et al. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ 1998; 317: 1549-53
67. Stanley CA, Baker L. The causes of neonatal hypoglycemia. N Engl J Med 1999; 340: 1200-1
68. Naye RL, Peters EC. Antenatal hypoxia and low IQ values. Am J Dis Child 1987; 141: 50-4
69. Hack M, Klein NK, Taylor HG. Long-term developmental outcomes of low birth weight infants. Future Child 1995; 5: 176-96
70. Kok JH, den Ouden AL, Verloove-Vanhorick SP, et al. Outcome of very preterm small for gestational age infants: the first nine years of life. Br J Obstet Gynaecol 1998; 105: 162-8
71. Strauss RS. Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort. JAMA 2000; 283: 625-32
72. Nimrod CA, Gruslin A. Biology of normal and deviant fetal growth. In: Reece EA, Hobbins JC, editors. Medicine of the fetus and mother. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1999: 267-78
73. Barker DJP. The long-term outcome of retarded fetal growth. Clin Obstet Gynecol 1997; 40: 853-63
74. Hales CN. Non-insulin-dependent diabetes mellitus. Br Med Bull 1997; 53: 109-22
75. Law CM, de Swiet M, Osmond G, et al. Initiation of hypertension in utero and amplification throughout life. BMJ 1993; 306: 24-7
76. Forsen T, Eriksson JG, Tuomilehto J, et al. Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. BMJ 1999; 319: 1403-7
77. Leon DA, Lithell HO, Vagero D, et al. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915-29. BMJ 1998; 317: 241-5
78. Osmond C, Barker DJP, Winter PD, et al. Early growth and death from cardiovascular disease in women. BMJ 1993; 307: 1519-24
79. Rich-Edwards JW, Stampfer MJ, Manson JE, et al. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ 1997; 315: 396-400
80. Eriksson JG, Forsen T, Tuomilehto J, et al. Catch up growth in childhood and death from coronary heart disease: longitudinal study. BMJ 1999; 318: 427-31
81. Forsen T, Eriksson JG, Tuomilehto J, et al. Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: follow-up study. BMJ 1999; 315: 837-40
82. Dwyer T, Blizzard L, Morley R, et al. Within pair association between birth weight and blood pressure at age 8 in twins from a cohort study. BMJ 1999; 319: 1325-9
83. Woodall SM, Johnston BM, Breier BH, et al. Chronic maternal undernutrition in the rat leads to delayed postnatal growth and elevated blood pressure of offspring. Pediatr Res 1996; 40: 438-43
84. Page EW, Christianson R. The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. Am J Obstet Gynecol 1976; 125: 740-6
85. Brown MA, Buddle ML. Hypertension in pregnancy: maternal and fetal outcomes according to laboratory and clinical features. Med J Aust 1996; 165: 360-5
86. Kim CR, Vohr BR, Oh W. Effects of maternal hypertension in very-low-birth-weight infants. Arch Pediatr Adolesc Med 1996; 150: 686-91
87. Rey E, LeLorier J, Burgess E, et al. Report of the Canadian Hypertension Society consensus conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 1997; 157: 1245-54
88. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22
89. Department of Health. Report on confidential enquiries into maternal deaths in the United Kingdom 1991-93. London: HMSO, 1996
90. Magee LA, Ornstein MP, von Dadelszen P. Clinical review: management of hypertension in pregnancy. BMJ 1999; 318: 1332-6
91. von Dadelszen P, Ornstein MP, Bull S, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension. Lancet 2000; 355: 87-92
92. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301: 587-9
93. Magee LA. Best evidence-based medicine in perinatal pharmacology; trials are not enough [dissertation]. Toronto: University of Toronto, 1996
94. Moutquin JM, Garner PR, Burrows RF, et al. Report of the Canadian Hypertension Society consensus conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. CMAJ 1997; 157: 907-19
95. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353; 1258-65
96. Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999; 354: 810-16
97. Heyborne KD. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol 2000; 183: 523-8
98. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345: 1455-63
99. Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 300-3
100. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of preeclampsia. N Engl J Med 1995; 333: 201-5
101. Burrows RF, Burrows EA. The feasibility of a control population for a randomized control trial of seizure prophylaxis in the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1995; 173: 929-35
102. United States Food and Drug Administration labelling and prescription drug advertising: content and format for labelling for human prescription drugs. Fed Regist 1979; 44: 37434-67
103. Teratology Society Public Affairs Committee. FDA classification of drugs for teratogenic risk. Teratology 1994; 49: 446-7
104. Shear R, Rey E. BP and babies: hypertension in pregnancy. Can J CME 1999; Feb: 69-82
105. Umans JG, Lindheimer MD. Antihypertensive treatment. In: Lindheimer MD, Roberts JM, Cunningham FG, editors. Chesley's hypertensive disorders in pregnancy, 2nd ed. Stamford (CT): Appleton & Lange, 1999: 581-604
106. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137-50
107. Guyton AC. Blood pressure control - special role of the kidneys and body fluids. Science 1991; 252: 1813-6
108. Gress TW, Nieto J, Shahar E, et al., Atherosclerosis Risk in Communities Study, Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-12
109. Briggs GG, Freeman RK, Yaffe SJ, editors, Drugs in pregnancy and lactation. 4th ed. Baltimore (MD): Williams & Wilkins, 1994
110. Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. BMJ 1985; 290: 17-23
111. Gallery EDM, Hunyor SN, Gyory AZ. Plasma volume contraction: a significant factor in both pregnancy-associated hypertension (preeclampsia) and chronic hypertension in pregnancy. Q J Med 1979; 192: 593-602
112. Materson BJ, Reda DJ, Cushman WC, Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21
113. Ornstein M, von Dadelszen P, Magee LA. Clinical trials in pregnancy hypertension. In: Rubin PC, editor. Handbook of hypertension; pregnancy hypertension. 2nd ed. Amsterdam: Elsevier Science Publishers. In press
114. Magee LA, Elran E, Bull S, et al. Risks and benefits of β-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000; 88: 15-26
115. Magee LA. Fetal growth restriction. Lancet 2000; 355: 1366-72
116. Lydakis C, Lip GYH, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12: 541-7
117. Lip GYH, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol 1997; 79: 1436-8
118. Easterline TR, Brateng D, Schmucker B, et al. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 1999; 93: 725-33
119. Gallery EDM, Lindheimer MD. Alternations in volume homeostasis. In: Lindheimer MD, Roberts JM, Cunningham FG, editors. Chesley's hypertensive disorders in pregnancy. 2nd ed. Stamford (CT): Appleton & Lange, 1999; 327-47
120. Ducey JP, Knape KG. Maternal esmolol administration resulting in fetal distress and cesarean section in a term pregnancy. Anesthesiology 1992; 77: 829-32
121. Hurst JA, Houlston RS, Roberts A, et al. Transverse limb deficiency, facial clefting and hypoxic renal damage; an association with treatment of maternal hypertension? Clin Dysmorphol 1995; 4: 359-63
122. Staessen JA, Fagard R, Thijs L, et al., Systolic Hypertension-Europe (Syst-Eur) Trial Investigators, Morbidity and mortality in the placebo-controlled European trial on isolated systolic hypertension in the elderly. Lancet 1997; 360: 757-64
123. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-9
124. Brouwer RM, Bolli P, Erne P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. Cardiovasc Pharmacol 1985; 7: S88-S91
125. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996; 174: 823-8
126. Impey L. Severe hypertension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993; 100: 959-61
127. Waisman GD, Mayorga LM, Camera MI, et al. Magnesium plus nifedipine; potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol 1988; 159: 308-9
128. Brown MA, McCowan LME, North RA, et al. Withdrawal of nifedipine capsules: jeopardising the treatment of acute severe hypertension in pregnancy. Med J Aust 1997; 166: 643
129. Ales K. Magnesium plus nifedipine. Am J Obstet Gynecol 1990; 162:288
130. Yemini M, Shoham Z, Dgani R, et al. Lupus-like syndrome in a mother and newborn following administration of hydralazine: a case report, Eur J Obstet Gynecol Reprod Biol 1989; 30: 193-7
131. Lip GYH, Churchill D, Beevers M, et al. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997; 350: 1446-7
132. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep 1997; 46: 240-1
133. Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994; 50: 399-409
134. Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol 1998; 38: 306-11